Your browser is no longer supported. Please, upgrade your browser.
VCEL Vericel Corporation daily Stock Chart
Vericel Corporation
Index- P/E- EPS (ttm)-0.27 Insider Own1.50% Shs Outstand44.92M Perf Week-4.96%
Market Cap728.18M Forward P/E52.72 EPS next Y0.30 Insider Trans-2.66% Shs Float44.62M Perf Month8.45%
Income-11.50M PEG- EPS next Q-0.21 Inst Own99.90% Short Float14.13% Perf Quarter7.57%
Sales122.70M P/S5.93 EPS this Y-8.20% Inst Trans8.03% Short Ratio9.99 Perf Half Y-8.14%
Book/sh2.46 P/B6.47 EPS next Y433.30% ROA-8.10% Target Price23.40 Perf Year-14.41%
Cash/sh1.78 P/C8.92 EPS next 5Y- ROE-11.30% 52W Range6.78 - 19.77 Perf YTD-8.51%
Dividend- P/FCF- EPS past 5Y37.10% ROI-10.10% 52W High-19.47% Beta2.98
Dividend %- Quick Ratio6.00 Sales past 5Y32.60% Gross Margin68.30% 52W Low134.81% ATR0.78
Employees241 Current Ratio6.40 Sales Q/Q22.50% Oper. Margin-10.50% RSI (14)50.01 Volatility5.44% 4.37%
OptionableYes Debt/Eq0.00 EPS Q/Q-61.00% Profit Margin-9.40% Rel Volume1.21 Prev Close16.82
ShortableYes LT Debt/Eq0.00 EarningsAug 05 BMO Payout- Avg Volume630.82K Price15.92
Recom1.50 SMA20-2.00% SMA505.38% SMA2003.73% Volume762,444 Change-5.35%
Oct-09-19Initiated H.C. Wainwright Buy $19
Feb-28-19Downgrade Needham Buy → Hold
Aug-08-18Reiterated Needham Buy $15 → $14
Jul-16-18Upgrade Ladenburg Thalmann Neutral → Buy
Apr-04-18Initiated Leerink Partners Outperform $15
Mar-06-18Reiterated Needham Buy $5 → $15
Mar-06-18Downgrade Ladenburg Thalmann Buy → Neutral
Mar-05-18Reiterated BTIG Research Buy $8 → $13
Jun-21-17Initiated BTIG Research Buy $6
Mar-13-17Reiterated Needham Buy $9 → $6
Dec-22-16Initiated Piper Jaffray Overweight $6
Nov-09-16Reiterated Needham Buy $12 → $9
Apr-05-16Downgrade BofA/Merrill Buy → Neutral
Mar-11-16Upgrade Needham Hold → Buy $12
Aug-05-20 08:00AM  
Jul-22-20 08:30AM  
Jul-15-20 08:33AM  
Jul-09-20 08:30AM  
Jun-30-20 07:00AM  
Jun-23-20 01:48PM  
May-28-20 03:38AM  
May-27-20 11:14AM  
May-26-20 09:27AM  
May-13-20 08:30AM  
May-06-20 12:02AM  
May-05-20 09:34AM  
Apr-22-20 08:30AM  
Apr-10-20 09:00AM  
Apr-08-20 08:30AM  
Apr-02-20 02:58PM  
Mar-31-20 09:39AM  
Mar-10-20 03:17AM  
Mar-04-20 08:29AM  
Mar-03-20 09:28AM  
Feb-25-20 08:00AM  
Feb-24-20 10:04AM  
Feb-19-20 08:00AM  
Feb-14-20 09:49AM  
Feb-13-20 08:48AM  
Feb-12-20 08:06AM  
Feb-11-20 08:00AM  
Feb-10-20 10:20AM  
Jan-31-20 12:46PM  
Jan-09-20 08:00AM  
Jan-06-20 06:30AM  
Dec-19-19 07:07AM  
Dec-17-19 02:46PM  
Dec-11-19 09:48AM  
Dec-06-19 07:20AM  
Nov-06-19 10:55AM  
Nov-05-19 08:00AM  
Oct-31-19 03:43PM  
Oct-28-19 08:18PM  
Oct-22-19 08:30AM  
Oct-09-19 03:09PM  
Oct-02-19 07:30AM  
Sep-27-19 08:00AM  
Sep-23-19 02:19PM  
Sep-18-19 08:00AM  
Sep-04-19 08:00AM  
Aug-08-19 06:28PM  
Aug-06-19 12:23PM  
Aug-01-19 08:00AM  
Jul-23-19 08:00AM  
Jul-09-19 10:43PM  
Jun-29-19 08:15AM  
Jun-18-19 10:30AM  
May-29-19 07:30AM  
May-15-19 08:00AM  
May-14-19 05:40PM  
May-09-19 11:30AM  
May-08-19 06:24AM  
May-07-19 08:53PM  
May-06-19 07:45AM  
May-05-19 05:49PM  
Apr-30-19 10:32AM  
Apr-25-19 08:30AM  
Apr-03-19 08:30AM  
Apr-01-19 08:10AM  
Mar-06-19 01:17PM  
Mar-04-19 08:30AM  
Mar-01-19 12:16AM  
Feb-26-19 04:08PM  
Feb-22-19 04:43PM  
Feb-20-19 08:30AM  
Feb-12-19 08:30AM  
Jan-11-19 12:12PM  
Jan-04-19 12:02PM  
Jan-03-19 09:39AM  
Jan-02-19 08:33AM  
Dec-27-18 09:30AM  
Dec-26-18 07:45AM  
Dec-19-18 08:49AM  
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. It markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to dilated cardiomyopathy. In addition, its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for debridement of severe thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Halpin MichaelChief Operating OfficerJun 23Option Exercise7.2014,751106,20716,373Jun 24 04:19 PM
Halpin MichaelChief Operating OfficerJun 23Sale15.0114,751221,4131,622Jun 24 04:19 PM
Halpin MichaelChief Operating OfficerJun 16Option Exercise2.652,8907,6595,624Jun 18 04:03 PM
Halpin MichaelChief Operating OfficerJun 16Sale15.004,00260,0301,622Jun 18 04:03 PM
Colangelo DominickPresident and CEOMay 08Option Exercise2.7513,12536,094210,492May 08 04:09 PM
ZERBE ROBERT L MDDirectorApr 29Option Exercise0.001,750019,295May 01 04:17 PM
GILMAN STEVEN CDirectorApr 29Option Exercise0.001,75001,750May 01 04:15 PM
Hagen HeidiDirectorApr 29Option Exercise0.001,75001,750May 01 04:14 PM
MCLAUGHLIN KEVIN FDirectorApr 29Option Exercise0.001,75001,750May 01 04:13 PM
Wotton Paul KDirectorApr 29Option Exercise0.001,75001,750May 01 04:12 PM
Rubino Alan LDirectorApr 29Option Exercise0.001,75002,644May 01 04:09 PM
MICHEL GERARD JCFO and VP, Corp. DevelopmentApr 01Option Exercise2.9891,157271,482253,865Apr 03 04:02 PM
Colangelo DominickPresident and CEOFeb 13Option Exercise2.4023,43856,204196,229Feb 18 04:26 PM
Halpin MichaelChief Operating OfficerFeb 06Option Exercise0.001,87503,164Feb 10 05:04 PM
Colangelo DominickPresident and CEOFeb 06Option Exercise0.006,9370175,970Feb 10 05:03 PM
MICHEL GERARD JCFO and VP, Corp. DevelopmentFeb 06Option Exercise0.003,0000162,732Feb 10 05:02 PM
Halpin MichaelChief Operating OfficerNov 11Option Exercise2.6515,04739,87516,081Nov 12 04:03 PM
Halpin MichaelChief Operating OfficerNov 11Sale18.5315,047278,8211,034Nov 12 04:03 PM
Colangelo DominickPresident and CEOOct 02Option Exercise2.6516,25043,063169,033Oct 03 04:12 PM
MICHEL GERARD JCFO and VP, Corp. DevelopmentOct 02Option Exercise2.5036,07790,249159,732Oct 03 04:01 PM
Colangelo DominickPresident and CEOOct 01Option Exercise2.7558,125159,844170,908Oct 03 04:03 PM
Colangelo DominickPresident and CEOOct 01Option Exercise2.6540,000106,000152,783Oct 03 04:12 PM
Colangelo DominickPresident and CEOOct 01Sale14.8858,125864,650112,783Oct 03 04:03 PM
MICHEL GERARD JCFO and VP, Corp. DevelopmentAug 14Option Exercise3.0217,00051,340140,182Aug 16 04:06 PM
MICHEL GERARD JCFO and VP, Corp. DevelopmentAug 14Sale16.6217,000282,547123,182Aug 16 04:06 PM